Today: 20 May 2026
BMNR stock rises as BitMine pushes last-minute vote on plan to lift share cap to 50 billion
14 January 2026
2 mins read

BMNR stock rises as BitMine pushes last-minute vote on plan to lift share cap to 50 billion

New York, January 14, 2026, 14:20 ET — Regular session

  • Shares of BitMine Immersion Technologies (BMNR) climbed roughly 4% after the company called on shareholders to support a charter amendment before its annual meeting
  • The proposal seeks to raise the company’s authorized shares from 500 million to 50 billion, a move it argues is necessary to continue issuing stock
  • A new quarterly filing highlighted just how quickly crypto price swings can impact reported results

Shares of BitMine Immersion Technologies, Inc. climbed roughly 4% to $32.46 during Wednesday’s afternoon session. The crypto-focused firm urged shareholders to back a charter amendment before its annual meeting. Volume surged past 51 million shares.

The push is moving against a tight deadline. A transcript linked to a filing implored investors to cast their votes by Jan. 14, 11:59 p.m. Eastern, cautioning that the company might “soon” run out of shares to issue for purchases or deals.

BMNR has effectively turned into a leveraged play on ether, the Ethereum network’s native token. Ether climbed roughly 4.9% on the day, while bitcoin gained around 3.6%, pushing crypto-related stocks higher.

The charter vote covers a massive increase. BitMine’s proxy statement proposes boosting authorized common shares from 500 million to 50 billion. It also warns that the board might issue more stock without needing another shareholder vote, as long as it complies with laws and exchange rules. The filing highlights dilution risk and points out that extra shares could serve as a defense against takeovers.

Just two days prior, the company revealed a balance sheet snapshot shedding light on its urgency. In a Jan. 12 SEC filing, BitMine reported holding 4,167,768 ether as of Jan. 11, 7:00 p.m. ET, alongside 193 bitcoin and $988 million in cash. It valued its “crypto + total cash + ‘moonshots’” at $14.0 billion. Fundstrat’s Chairman Tom Lee noted the charter includes an unusual clause demanding 50.1% of all outstanding shares to approve any increase, warning the firm was “soon to exhaust its current 500 million authorization.”

A quarterly report released Tuesday revealed a steep downside: BitMine logged a net loss of $5.20 billion for the quarter ending Nov. 30, 2025. That figure was largely shaped by a $5.25 billion unrealized loss on its digital-asset portfolio. At quarter’s close, the company reported $10.56 billion in digital assets valued at fair market price, alongside $887.7 million in cash and equivalents. The filing also confirmed BitMine had 454.9 million shares outstanding as of Jan. 12.

BitMine points to staking in its filings—a method where ether is locked up to validate transactions on Ethereum, earning rewards in return. While it can bring in income, the fundamental risk remains: the treasury’s value still fluctuates with crypto prices.

Traders face a straightforward choice ahead. Should shareholders greenlight the charter amendment, BitMine gains flexibility to issue more stock—a crucial lever it’s used to back its ether strategy—and to chase mergers or other deals. If the amendment doesn’t pass, the company has cautioned that its buying pace could stall, limited by the existing authorization cap.

There’s a trade-off here. Approving a larger share authorization raises the risk of dilution—particularly for a company that’s already boosted its share count quickly. Even management’s proxy materials warn the stock price might drop if share issuance speeds up. Then there’s crypto: a dip in ether’s price hits straight through to reported losses under fair-value accounting.

BitMine often gets compared to Strategy, the bitcoin-treasury firm, but its focus is squarely on ether and the financing behind buying more. That’s why this week’s vote, rather than a product rollout or earnings report, is dictating sentiment.

Investors are focused on the Jan. 14 voting deadline and the annual meeting set for Jan. 15. They’re eager to see if the share increase hits the needed threshold and to hear the company’s plans on the speed of future crypto purchases.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next
Previous Story

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Uber stock slips after NYC tipping report targets Uber Eats, as earnings date and new profit metrics loom
Next Story

Uber stock slips after NYC tipping report targets Uber Eats, as earnings date and new profit metrics loom

Go toTop